MHRA-100369-PIP01-21-M02 (update)

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
Invented Name
  • Galafold 123 mg capsules
  • Galafold
  • Galafold
PIP Number MHRA-100369-PIP01-21-M02 (update)
Pharmaceutical form(s)
  • Capsule, hard
  • Dispersible tablet
Therapeutic area
Therapeutic area:
  • Endocrinology-Gynaecology-Fertility-metabolism
Conditions / Indications
Conditions / Indications:
  • Treatment of Fabry disease
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
  • Amicus Therapeutics UK Ltd
  • Country United Kingdom
  • Tel 0016096623809
  • Email
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):MIGALASTAT HYDROCHLORIDE.pdf
Published Date 30/01/2024